Key result
Recombinant aminopeptidase A accelerates blood pressure recovery after angiotensin I and II infusion in mice.
Why the study?
Because several RAS peptides contain an N-terminal aspartate, the study investigated recombinant APA's hydrolytic action across multiple angiotensin peptides and whether Ang-(1-12) pressor activity is altered by recombinant APA or genetic APA deficiency.
Does recombinant aminopeptidase A cleave N-terminal aspartate from angiotensin peptides and attenuate the acute blood pressure pressor response to Ang I, Ang II, and Ang-(1-12) in mice?
Does recombinant aminopeptidase A cleave N-terminal aspartate from angiotensin peptides and attenuate the acute blood pressure pressor response to Ang I, Ang II, and Ang-(1-12) in mice?
Preclinical evidence demonstrates that aminopeptidase A degrades N-terminal aspartate angiotensin peptides and blunts Ang I and Ang II pressor responses, while revealing that Ang-(1-12) elevates blood pressure partly through a mechanism resistant to circulating APA and ACE2 degradation.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; leaves open APA modulation of angiotensin pathways for further preclinical study.
Aminopeptidase A (APA) cleaves a single aspartate residue from the amino terminus of peptides within the renin angiotensin system (RAS). Since several RAS peptides contain an N-terminal aspartate, we developed an assay to evaluate the effect of recombinant APA on the cleavage of Ang I, Ang II, Ang-(1-7), Ang-(1-9), and Ang-(1-12). The latter peptide has been proposed to be a functional Ang II-forming substrate with a hypertensive action attributable to the formed Ang II acting on AT1 receptors. Here we investigated the following: (a) the hydrolytic action of APA on Ang-(1-12), Ang I (1-10), Ang-(1-9), Ang II and Ang-(1-7) and (b) whether Ang-(1-12) pressor activity is altered by recombinant APA (r-APA) or genetic APA deficiency. We found that (a) r-APA cleaves the N-terminal aspartate of not only Ang II but also [Ang-(1-12), Ang I (1-10), Ang-(1-9)] and [Ang-(1-7)]; (b) the pressor activity of Ang-(1-12) was abolished in the presence of Lisinopril or Telmisartan; (c) r-APA significantly attenuated the pressor activities of infused Ang I and Ang II but not Ang-(1-12); and (d) r-ACE2 also did not attenuate the pressor effect of infused Ang-(1-12). Thus, in addition to increasing blood pressure indirectly via the formation of Ang II, Ang-(1-12) increases blood pressure by an Ang II-independent mechanism. We conclude that APA has an antihypertensive effect attributable to rapid degradation of Ang II, and this action may have a therapeutic potential in forms of hypertension that are Ang II-dependent. In addition, APA metabolizes Ang-(1-12), a peptide that has a prohypertensive action, in part, as a source of Ang II formation but also by a yet to be determined action independent of Ang II.
No takes yet. Share an insight, caveat, or question.
Wysocki et al. (2025) studied Angiotensin-induced acute hypertension. Recombinant aminopeptidase A (rAPA) vs. Sterile PBS (0.4 mL) vehicle control was evaluated on Systolic blood pressure (SBP) recovery after Ang II bolus injection (p=0.0082). Recombinant aminopeptidase A accelerated systolic blood pressure recovery after Ang I and Ang II infusion in mice, but did not attenuate Ang-(1-12).
Synapse has enriched 10 related papers. Consider them for comparative context: